Total Raised

$135.87M

Investors Count

21

Deal Terms

2

Lunit Funding, Lunit Valuation & Lunit Revenue

12 Fundings

Lunit's latest funding round was a IPO for on July 21, 2022.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

7/21/2022

IPO

0

FY undefined

2

11/25/2021

Series D

$61M

0

FY undefined

10

7/19/2021

Series C - II

$26M

0

FY undefined

15

10/12/2020

Incubator/Accelerator - II

0

FY undefined

10

3/26/2020

Incubator/Accelerator

0

FY undefined

10

Date

7/21/2022

11/25/2021

7/19/2021

10/12/2020

3/26/2020

Round

IPO

Series D

Series C - II

Incubator/Accelerator - II

Incubator/Accelerator

Amount

$61M

$26M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

2

10

15

10

10

Financials

Income Statement

Income Statement

12/31/2021

12/31/2020

12/31/2019

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2021

12/31/2020

12/31/2019

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2021

12/31/2020

12/31/2019

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Lunit Deal Terms

2 Deal Terms

Lunit's deal structure is available for 2 funding rounds, including their Series B from July 04, 2018.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Lunit Investors

21 Investors

Lunit has 21 investors. HealthQuest Capital invested in Lunit's Series D funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/25/2021

11/25/2021

1
Series D

Growth Equity

California

11/25/2021

11/25/2021

1
Series D

Non-Profit Foundation

United States

11/25/2021

11/25/2021

1
Series D

Corporate Venture

Singapore

00/00/0000

00/00/0000

Casdin Capital

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Tybourne Capital Management

Subscribe to see more

Asset/Investment Management

Hong Kong

First funding

11/25/2021

11/25/2021

11/25/2021

00/00/0000

00/00/0000

Last Funding

11/25/2021

11/25/2021

11/25/2021

00/00/0000

00/00/0000

Investor

Casdin Capital

Tybourne Capital Management

Rounds

1
Series D
1
Series D
1
Series D

Subscribe to see more

Subscribe to see more

Board Seats

Type

Growth Equity

Non-Profit Foundation

Corporate Venture

Venture Capital

Asset/Investment Management

Location

California

United States

Singapore

New York

Hong Kong

You May Also Like

QUIBIM Logo
QUIBIM

Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.

A
Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Viz.ai Logo
Viz.ai

Viz.ai aims to use artificial intelligence and deep learning to automatically identify suspected LVOs (large vessel occlusion) on CTA imaging with the aim of alerting a patient's physician within minutes. The company was founded in 2016 and is based in San Francisco, California.

Infervision Logo
Infervision

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Ultromics Logo
Ultromics

Ultromics is a global health technology company that provides autonomous echocardiography analysis through AI solutions – empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

ScreenPoint Medical Logo
ScreenPoint Medical

ScreenPoint Medical, based in Nijmegen, has developed smart software for improving results of breast cancer screening. This software reads mammograms like a human reader and supports radiologists by identifying and interpreting potential problem areas on x-ray images. This reduces the chance of missing tumors and may be used to organize screening more efficiently.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.